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ABSTRACT
Sumoylation, the covalent attachment of the SUMO peptide (small ubiquitin-related modifier) to 
cellular proteins, is a post-translational modification affecting many cellular processes, including 
transcription. Sumoylated proteins are found specifically on the promoters of transcriptionally 
active genes. Since the role of SUMO on the promoters for constitutive genes remains largely 
unknown, we applied the “anchor-away” technology to generate a yeast strain in which the 
SUMO conjugating enzyme, Ubc9, could be depleted from nuclei, allowing us to study the 
effects on transcription.
The strain had significantly lower SUMO levels upon rapamycin treatment. However, it also had 
low levels of basal sumoylation, which reduced further with rapamycin. This rapid disappearance 
of sumoylated proteins shows that sumoylation is very labile, probably because of the SUMO 
protease Ulp1’s activity. The lower sumoylation in the strain was associated with decreased 
transcription, reduced RNA Pol II recruitment and lower levels of active histone marks for some 
genes.
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1Chapter 1: Introduction
1.1 Post-translational Modifications:
Post-translational modifications (PTMs) are processing events which can change the properties of 
proteins by proteolytic cleavage or by the covalent addition of a modifying group to one or more amino 
acid residues (15). These modifications can be extremely diverse and can determine a protein’s activity 
state, localization, turnover, interactions with other proteins and more (15). Some of the common 
PTMs that are studied around the world include acetylation, methylation, glycosylation, 
phosphorylation, ubiquitination and sumoylation. Many PTMs can also work in combination with 
others as part of extensive ‘crosstalk’ to enhance the level of complexity in the cell.
1.2 Sumoylation:
Sumoylation is a post-translational modification that affects proteins in a vast range of cellular 
processes (1-3). It involves the covalent reversible attachment of the SUMO peptide (small ubiquitin-
related modifier) to specific lysine residues of cellular proteins. The modified residues usually fall 
within a consensus motif, ΨKxE (Ψ is a large hydrophobic residue, K the residue modified and x any 
amino acid) (7) (Fig 1A). Other post-translational modifications, such as phosphorylation, can also 
stimulate sumoylation (18). Although the small ~12 kDa SUMO peptide shares a similar three-
dimensional structure as ubiquitin (Fig 1B), they share less than 20% amino-acid sequence identity and 
are different in their overall surface-charge distribution. All SUMO proteins have an unstructured 
stretch of 10-25 amino acids at their N termini which is not seen in any other ubiquitin-related proteins 
(Fig 1A). The budding yeast Saccharomyces cerevisiae expresses a single form of SUMO, encoded by 
the essential SMT3 gene, while three active isoforms, SUMO-1, SUMO-2 and SUMO-3, exist in 
vertebrates. The SUMO-2 and SUMO-3 proteins share ~97% sequence identity and are sometimes 
collectively termed as SUMO-2/3 (19). SUMO-1 is approximately 48% identical to SUMO-2 and 46% 
identical to SUMO-3 (20), while also having the highest sequence identity to the yeast Smt3 protein 
2(19) (Fig 1A). However, it does not form polysumoylated chains whereas the mammalian SUMO-2/3 
and the yeast Smt3 do (21). 
Figure 1: SUMO vs Ubiquitin
A) Amino acid sequence alignments of ubiquitin and the four human SUMO homologs. Identities indicated in bold and 
similarities are shaded. The SUMO consensus motif for SUMO chain formation on SUMO-2, SUMO-3 and SUMO-4 is 
boxed in yellow, with the SUMO acceptor lysine (K) in the motif boxed in red. Ubiquitin Ls48 and Lys63, the common 
sites for ubiquitin polymerization, are boxed in red. The cleavage site, used to produce mature SUMO peptides with C-
terminal glycine-glycine residues, is also indicated. B) Ribbon diagrams show the three-dimensional structural similarity 
between SUMO-1 and ubiquitin. Secondary structures indicated: β sheets are green and α helices are red. Note that SUMO 
has an N-terminal extension not seen in ubiquitin. Figure adapted from Gill (40).
1.3 The Mechanism of Sumoylation:
SUMO, like other members of the ubiquitin-like protein (UBL) family, covalently attaches to its target 
proteins in a process that is very similar to ubiquitin-protein conjugation, involving a cascade of 
enzymatic activities involving E1-activting enzymes, a sole E2-conjugating enzyme, and in some 
cases, an E3 ligating enzyme (22). SUMO is initially synthesized as an inactive precursor with an 
extension on the peptide’s C-terminus (19). A SUMO protease (Ubiquitin-like specific protease (Ulp1) 
3in yeast or SENtrin-specific protease (SENP) in humans) then cleaves downstream of a Gly-Gly motif 
at the C-terminal proximal end to form mature SUMO ready to conjugate (Fig 2).
Figure 2: Di-glycine motif of the Ubl protein family
The SUMO peptide is part of the Ubl superfamily of proteins. These proteins require processing to reveal a di-glycine 
motif. This motif is used during its conjugation to target proteins (41). 
The carboxy-terminus of this mature SUMO is activated by the heteromeric SUMO-activating enzyme 
E1 (Aos1/Uba2 in yeast and Sae1/Sae2 in mammals) in an ATP-dependent manner, forming a high-
energy thioester bond with the E1. SUMO is then transferred to the active-site cysteine of the E2 
SUMO-conjugating enzyme (Ubc9) before being transferred to the lysine side chain on the target 
proteins (19). Protein sumoylation can be facilitated by one of a small number of SUMO E3 ligases, 
such as Siz1, Siz2, Zip3 and Mms21, that have been discovered in yeast (24-25), usually accentuating 
conjugation specificity (23) (Fig 3). Target proteins can be sumoylated on a single lysine 
(monosumoylation), on multiple lysines (multisumoylation), or SUMO chains can be formed on one or 
more lysine residues (polysumoylation) (19). 
4Figure 3: The Sumoylation pathway
Pre-mature SUMO undergoes maturation through SUMO-specific protease cleavage to display its C-terminal Gly-Gly motif 
(Step 1). This mature SUMO is then activated by the E1 heterodimer enzyme in an ATP-dependent reaction (Step 2). The 
activated SUMO is then transferred to Ubc9, the sole E2 enzyme (Step 3). E3 ligases can sometimes help Ubc9 transfer the 
SUMO peptide to the specific lysine acceptor site of the target proteins (Step 4). Sumoylation can be removed from the 
conjugated species by the action of SUMO proteases (Step 5). Adapted from Dasso (42).
1.4 De-Sumoylation:
Being a reversible PTM, SUMO modifications can be removed from its substrates by SUMO –specific 
proteases, which have isopeptidase activity. These proteases specifically cleave the bond between the 
SUMO and its substrate. Three known classes of SUMO proteases, with the SENP family being the 
largest, have been identified in vertebrates, with seven well characterized members in humans. In 
yeast, where the SUMO proteases were initially identified, Ulp1 and Ulp2 have been found performing 
this role (Table 1). With multiple enzymes at play, sumoylation is a highly dynamic process in which 
the steady-state levels of SUMO are tightly regulated by the complex interplay of the SUMO E1, E2, 
E3 and various proteolytic enzymes and plays crucial roles in many cellular pathways (26-27).
5Table 1: Known enzymes involved in the sumoylation pathway in yeast and mammals
Proteins/Enzymes Yeast (S. cerevisiae) Mammals (H. sapiens)
SUMO Smt3 SUMO-1, SUMO-2 and SUMO-3
E1 (activating enzyme) Aos1, Uba2 Sae1 and Sae2
E2 (conjugating enzyme) Ubc9 Ubc9
E3 (ligating enzyme) Siz1, Siz2, Mms21 and 
Zip3
PIAS1, PIAS3, PIASxα, PIASxβ, 
PIASy, RanBP2, TOPORS, PC2, 
HDAC4 and Mms21
SUMO proteases Ulp1 and Ulp2 SENP1, SENP2, SENP3, SENP5, 
SENP6 and SENP7
Not surprisingly, dysregulation of sumoylation is associated with numerous diseases, including 
Alzheimer’s, Huntington’s, Parkinson’s and many cancers (28-29). For instance, in metastatic breast 
cancer cells, sumoylation levels are significantly elevated, while both Ubc9 and SUMO protease 
expression levels were found to be altered in a large number of tumors (30-32). 
1.5 Connection to the Ubiquitin Proteolysis Pathway:
Although sumoylation has not been directly found to signal protein degradation, it can act as a 
secondary signal for proteolysis (33). Poly-sumoylated proteins can be recognized by the SUMO-
interacting motifs (SIMs) of a class of E3 ubiquitin ligating enzymes, also known as SUMO-targeted 
ubiquitin E3 ligases (STUbLs). A RING finger domain of the STUbL, along with an E2 ubiquitin 
conjugating enzyme, then results in the ubiquitination of the target protein (Fig 4). The 26S proteasome 
can then be recruited eventually degrading the protein (34). The sumoylation of acute promyelocytic 
6leukemia (PML) protein is recognized by the RNF4 STUbL in this fashion, facilitating its 
polyubiquitination and proteasome-dependent degradation (35) (Fig 4). However, in some cases, 
sumoylation can also compete with ubiquitin for specific Lys acceptor sites, thus preventing its 
ubiquitination and degradation by the proteasome (36). 
Figure 4: Schematic Diagram of the connection between sumoylation and ubiquitination
In some cases, poly-sumoylation can lead to interaction with the SIMs on the E3 ubiquitin ligases for sumoylated proteins 
(E3-S). These enzymes bind to the E2 ubiquitin conjugating enzyme through a RING domain conjugated to it, beginning 
poly-ubiquitination. This protein can then be degraded by the 26S proteasome (34).
1.6 Sumoylation of Transcription Factors:
More than 6000 proteins have been recognized as potential targets for sumoylation (4) 
with the process being implicated in controlling many facets of cell physiology, including cell-
cycle regulation, transport, DNA replication and repair, and transcription (5-8). Although 
sumoylated proteins are found throughout the cell, those involved in transcription are one of the 
7largest groups of sumoylation targets (2, 3). This included many transcriptional activators, 
repressors, co-regulators and general transcription factors in both yeast and mammalian cells. 
Sumoylation’s effect on different transcription factors is diverse. However, in a vast majority of 
cases, this modification is associated with transcriptional repression, accomplished by different 
SUMO-mediated mechanisms. For instance, the sumoylation of transcription factor Elk1 
stimulates the recruitment of the histone deacetylase HDAC-2, reducing the histone acetylation 
levels and thereby inhibiting transcription (37). However, when this pathway is activated by ERK, 
Elk-1 is phosphorylated together with a loss of SUMO and HDAC leading to a full activation of 
target genes. Several studies have also found evidence of sumoylation being involved in 
activating transcription. For example, the SUMO modification of p53 enhances its ability to 
activate reporter genes possibly by competing against Mdm2-mediated ubiquitination, which 
would otherwise target it for degradation (38-39). 
Chromatin immunoprecipitation (ChIP) experiments in budding yeast showed that Ubc9 is 
recruited to promoters of inducible genes when they are activated, which coincides with the 
striking appearance of sumoylated proteins in this region (9). Further, impairing sumoylation 
(with a strain expressing partially defective Ubc9) does not affect induction of these genes, but 
rather prolongs their expression, suggesting that sumoylation of proteins at promoters of activated 
genes is important for shutting genes off when appropriate. Analysis of the inducible ARG1 gene 
showed that sumoylation promotes the clearance of its activator, Gcn4, from its promoter, which 
can explain how sumoylation facilitates shutting genes off (9)
ChIP analyses, including genome-wide studies, showed that sumoylated proteins are also 
found at promoters of constitutively active genes, but not repressed or silent genes, in both yeast 
and human cells, pointing to a correlation between sumoylation and active transcription (9-10). 
8However, Ubc9 was not detected at promoters of constitutive yeast genes suggesting that 
promoter-associated proteins are sumoylated before they associate with these genes. This also 
suggests that sumoylation plays a different role at constitutive gene promoters than at inducible 
promoters. One of the main goals of this study was to determine how constitutive expression is 
affected by sumoylation.
Most literature on the function of sumoylation on gene promoters in the context of transcription is 
focused on transcription factors that are gene specific. These experiments resort to mutating 
sumoylation sites by mutation of the target lysine residue(s) to non-sumoylatable arginine(s), 
thereby blocking sumoylation of the specific protein. Since both the SMT3 and UBC9 are 
essential genes, examining the effects of sumoylation using SMT3 and/or UBC9 null strains is not 
possible. As such, the function of global sumoylation on constitutive gene expression remains 
largely unknown. 
1.7 The Anchor Away Technique:
The anchor away (AA) technique was developed by Haruki et el. (11) as a method of 
conditionally depleting nuclei of specific proteins in living yeast cells to study the consequences 
of their absence in nuclear processes. By this technique, a nuclear protein of interest (the target) 
is relocalized to the cytoplasm by conditionally tethering it to an abundant cytoplasmic protein 
(the anchor) by rapamycin-induced heterodimerization. Specifically, the system takes advantage 
of the massive flow of ribosomal proteins through the nucleus during maturation prior to their 
cytoplasmic localization as a method of anchoring the nuclear protein of interest. In the anchor 
away strain, the ribosomal protein L13a (RPL13A) is fused to the human 12 kDa FK506 binding 
protein 12 (FKBP12) at its C-terminus. In the same yeast strain, the target nuclear protein of 
interest is expressed as a fusion to the 11 kDa FRB domain (FKBP12-rapamycin-binding 
9domain) of human mTOR (mammalian target of rapamycin), also at the C-terminus. When 
rapamycin is added to the cells, it binds to the FKBP12 domain, establishing an interaction 
surface for the FRB domain to form a tight ternary complex of nanomolar dissociation constant 
(11) (Fig 5). Although rapamycin is toxic to wild-type yeast, the strains used for this technique 
are derived from a rapamycin-resistant strain containing a mutated TOR1. They are also deleted 
for the FPR1 gene, the yeast homolog of human FKBP12, which is the most abundant FK506 
and rapamycin binding protein in S. cerevisiae. Deletion of FPR1 confers rapamycin resistance, 
while also reducing competition between FPR1 and the anchor-FKBP12 construct for binding to 
the FRB domain (11). 
The Anchor Away technique has been used a number of times to test the effects of 
depleting selected proteins from the nucleus. For instance, the technique was used to 
conditionally deplete Kin28, the TFIIH subunit that phosphorylates the CTD of RNA 
polymerase II, from the nucleus. It was shown that this depletion resulted in a dramatic increase 
in Mediator occupancy at the core promoter, which suggested that Kin28 was stimulating rapid 
promoter escape through dissociation of the Mediator from the preinitiation complex (PIC) (45). 
Similarly, Subramanian et al. (46) used the anchor away system to test whether the 
synaptonemal complex (SC) protein Zip1 was responsible for the loss of meiotic kinase, 
Mek1during meiosis. The conditional nature of the system offered an advantage over using Zip1 
null strains as it helped circumvent potential pleiotropic effects of earlier roles of Zip1 in 
centromere pairing and double stranded break (DSB) repairs (46).  
1.8 Overall Goal and Hypothesis of the Study:
This study was aimed at examining the role of nuclear sumoylation, particularly with 
respect to gene expression and constitutive transcription. To answer this question, the anchor 
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away system described above was used to conditionally deplete Ubc9 from yeast nuclei. The 
engineered anchor away strains in the experiments were derived from a rapamycin-resistant 
W303a strain of yeast, and express Ubc9-FRB fusion protein. The addition of rapamycin 
stimulates the dimerization of Ubc9-FRB and RPL13A-FKBP12, depleting the Ubc9 from the 
nucleus as the ternary complex is migrated to the cytoplasm (Fig 5). This is tantamount to 
preventing de novo sumoylation as Ubc9 is the sole conjugating E2 enzyme found in yeast cells.
 Considering that sumoylated proteins are detected on active gene promoters (9), it was 
hypothesized that SUMO plays a critical role in this process, potentially impairing the 
transcription of many constitutive genes.  
Once the specialized anchor away strains were engineered, the effects of Ubc9 nuclear 
depletion on cell viability, growth rates, constitutive gene expression and the efficiency of RNA 
Pol II recruitment were examined. Qualitative assays were also used to elucidate the localization 
of sumoylated proteins and to examine the levels of different histone marks (H3K4me3 and 
H3K9ac) as a function of reduced sumoylation. Our results showed that the anchor away strain had 
significantly lower SUMO levels upon rapamycin treatment, which also corresponded with lower 
growth rates (short-term) and cell viability (long-term).The strain, however, had lower basal 
sumoylation compared to the parental strain (i.e. even in the absence of rapamycin), and some 
constitutive gene promoters that started off with lower SUMO levels, did not show a further drop 
with rapamycin treatment. Sumoylation, however, was mostly associated with increased 
transcription and RNA Pol II recruitment.
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Figure 5: The Anchor Away System Schematic
In the specially engineered anchor away strain, the target protein (Ubc9) is fused to the FRB domain of mTOR, 
while the anchor protein RPL13A is fused to FKBP12. Upon adding rapamycin, FKBP12 and FRB dimerize. Since 
RPL13A leaves the nucleus upon maturation, the ternary complex (consisting of the target, anchor and rapamycin) 
is moved to the cytoplasm (11). This results in Ubc9 being sequestered from the nucleus to the cytoplasm.  
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Chapter 2: Materials and Methods
2.1 Yeast Strains and Plasmids:
Several yeast (Saccharomyces cerevisiae) strains were used in this study. Strains were derived from the 
W303 background strain. Strains expressing fusion proteins were marked on the genome with the 
KanMX marker gene cassette, and were generated by homologous recombination as previously 
outlined in literature (9). The presence of the fusion tag sequence in the strains was then confirmed by 
PCR and growth in the appropriate media.  
2.2 Yeast Media and Growth Conditions:
Yeast cultures (10 – 50 mL) were grown at 30°C in Synthetic Complete (SC; 0.17% YNB, 0.5% 
ammonium sulfate, and 2% glucose) media to an optical density A595 (O.D.) of 0.5-0.7, before treating 
them with rapamycin (stored in dimethyl sulfoxide, DMSO) at a final concentration of                                  
1 μg/mL. Some cultures were treated solely with DMSO as a control. 
For the RNA extraction and ChIP assays, the cultures were subjected to an additional treatment with 
the Alpha-factor mating pheromone (Zymo Research, 0.42 mg in 50 ml cultures) for 3 hours before the 
rapamycin treatment. This pheromone was used to arrest and synchronize yeast cells at the G1 phase 
before blocking de novo sumoylation by rapamycin treatment. The synchronization resulted in a 
homogenous cell culture which was important to isolate the effects of the experiment from the effects 
of normal cell-cycle progression (43). 
2.3 Transformation:
The appropriate strain was inoculated overnight and grown to saturation. It was then diluted and 
incubated in 10 mL of SC-media for 3 hours at 30o C the next day. The cells were then harvested by 
centrifugation at 3000 g for 5 min., and subsequently washed with 10 mL of sterile water. The pellet 
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was resuspended in 0.1 M LiAc, transferred to a new microfuge tube and centrifuged twice at top speed 
for 15 seconds. The cells were then resuspended in Transformation Mix (240 µL of PEG 3500 50% 
w/v, 36 µL of 1.0 M LiAc, 25 µL of boiled SS- carrier DNA, 40 µL of water & 10 µL of a cleaned 
PCR product with the required DNA), vortexed for 1 minute and then incubated in a 42o C water bath 
for 40 min. Following this incubation, the samples were centrifuged at top speed for 30 seconds and 
the transformation mix was removed. The yeast cells were then plated on to the appropriate plate at 30o 
C for 3 days. 
2.4 Spot Assay:
Cells were grown in appropriate liquid growth medium overnight, and their optical densities 
determined the following morning. Approximately 10,000 cells of each strain were spotted next to each 
other in the first position, and serial five-fold dilutions were spotted in adjacent positions, on 
appropriate solid medium plates. These plates were then incubated at 30˚C and were imaged for the 
growth of yeast. Images were taken daily for up to three days.
2.5 Liquid Growth Assay:  
The anchor away strain and the control parental strain were inoculated overnight in SC media and 
grown to saturation. Each strain was then diluted to an OD of 0.05 in 100 mL of SC media. Each of the 
culture was then split into two treatment groups (50 mL each) with half of them receiving 1:1000 
addition of dimethyl sulfoxide (DMSO) or 1 mg/mL rapamycin dissolved in DMSO. Over a 34 hour 
period, 12 OD readings were taken and recorded. The time points included were 0, 2, 4, 10, 12, 16, 24, 
26, 28, 30, 32 and 34 hours after the initial treatment. The experiment was repeated three times in total 
and the results were averaged and graphed using Microsoft Excel with the standard deviation shown as 
error bars on the graph.
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2.6 Chromatin Fractionation:
The strains were incubated and grown to saturation overnight. The next day, the cultures were diluted 
to 25 mL at an O. D of 0.2-0.25. They were then grown to an O. D of 0.5-0.6 before being treated with 
rapamycin (or control DMSO) for 30 min. The cells were pelleted at 2000 g or a minute at room 
temperature. They were then resuspended in 6.25 mL of a buffer consisting of 100 mM PIPES/KOH 
pH 9.4 &10μMDTT with rapamycin (or control DMSO), followed by incubation for 10 min. at 30o C 
with agitation. The cells were spun down (2000 g at room temperature for 3 min.) and resuspended 
again in 2.5 mL of a buffer consisting of 0.6 M sorbitol & 25 mMTris-HCl pH 7.5in YPD medium 
with rapamycin (or control DMSO). 10-15 mg/mL of the lysing enzyme zymolyase was also added to 
each sample at this point, followed by incubation for 20 min. at 30o C with agitation. The cells were 
again spun down (2000 g at room temperature for 3 min.) and resuspended in 2.5 mL of a buffer 
containing 0.7 M sorbitol, 25 mM Tris-HCl pH 7.5 in YPD medium with rapamycin (or control 
DMSO), followed once again by incubation for 20 min. at 30o C with agitation. The cells were pelleted 
by spinning them down at 2000 g in room temperature for 3 min. and then washed 3 times, each with 1 
mL of lysis buffer (0.4 M sorbitol, 150 mM potassium acetate, 2 mM magnesium acetate, 20 mM 
PIPES/KOH pH 6.8, 0.1% NP40, 1 mM PMSF, yeast protease inhibitor cocktail & 0.25 g NEM/100 
mL buffer). The cells were then resuspended in 400 μL lysis buffer, followed by the addition of Triton-
X 100 to a final concentration of 1%, mixing gently. Some of this lysed sample was removed and an 
equal volume of 2X SDS-PAGE sample buffer (4% SDS, 20% glycerol, bromophenol blue, 10% beta-
mercaptoethanol and 140 mMTris-HCl pH 8) was added to it. This served as the ‘whole cell extract’ 
control. The remaining lysed material was transferred to a microfuge tube and spun down at 20,817 g 
for 15 min. at 4o C. The supernatant obtained from this spin was labeled as the ‘soluble’ fraction and 
was mixed with an equal volume of 2X SDS-PAGE sample buffer (4% SDS, 20% glycerol, 
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bromophenol blue, 10% beta-mercaptoethanol and 140 mM Tris-HCl pH 8). The pellet obtained from 
the spin was washed once with 500μL lysis buffer and resuspended in 100μL of 2X SDS-PAGE 
sample buffer (4% SDS, 20% glycerol, bromophenol blue, 10% beta-mercaptoethanol and 140 mM 
Tris-HCl pH 8). This was labeled as the ‘chromatin’ fraction. All the three fractions (whole cell extract, 
chromatin and soluble) were then boiled for 5 min., cooled and finally frozen at -20o C or loaded 
directly to the SDS gels. 
2.7 Non-Denatured Yeast Extraction 
The strains were incubated, grown to saturation overnight and diluted to an O. D of 0.2-0.25 the next 
day. After reaching an O.D between 0.5 – 1.0, the cells were appropriately treated with rapamycin (or 
DMSO as a control) for 30 min., and then washed in IP buffer (50 mM Tris-HCl, pH 8 & 150 mM 
NaCl, 0.1% NP40, 1 mM PMSF, yeast protease inhibitor cocktail & 0.25 g NEM/100 mL buffer) and 
subsequently resuspended in 0.5 mL of IP buffer with 0.1 mM DTT and transferred to new microfuge 
tubes. 0.25 grams of acid washed glass beads were added to the tube and the cells were vortexed at 4o 
C for 30 min. (vortexed for 15 min., 5 min. on ice followed by vortexing again for 15 min.). The 
lysate/supermatant was transferred to a new microfuge tube and was centrifuged at 4o C at top speed 
for 5 min. The supernatant obtained from this spin was transferred to a new tube and this step was 
repeated. An equal volume of 2X SDS-PAGE sample buffer (4% SDS, 20% glycerol, bromophenol 
blue, 10% beta-mercaptoethanol and 140 mM Tris-HCl pH 8) was added to the lysate and was boiled 
for 3 min.
2.8 Western Blot & Antibodies: 
Equal amounts of protein samples were resolved on an appropriate-percentage SDS-PAGE gel (7.5%, 
10% or 12.5%) and transferred to nitrocellulose membranes (Biorad) followed by incubation with 
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blocking buffer [5% milk in 1X PBST {0.05% Tween-20 in 1% PBS (Fischer Scientific)}] for 30 min. 
at room temperature. The membranes were then probed with appropriate antibodies at the appropriate 
concentrations [GAPDH (1:5000), H3 (1:1000), H3K4me3 (1:1000), H3K9ac (1:1000), Smt3 (1:3000; 
for detection of sumoylation) & Ubc9-CTD (1:1000; for detecting the C terminal domain of the 
conjugation enzyme Ubc9)], overnight at 4˚C. Following incubation with the primary antibodies, these 
membranes were washed 3 times in 1X PBST for 5 min. each at room temperature. The blots were then 
incubated with the appropriate HRP conjugated secondary antibody (1:2000 for anti-goat IgG & 
1:5000 for anti-rabbit IgG; Thermo Fisher Scientific) for 30 min. at room temperature. The blots were 
then washed 3 times again and were later detected by chemiluminescence (ECL, Bio-Rad) using 
autoradiography or a MicroChemi chemiluminescence imager (DNR).  
2.9 RNA Extraction and Reverse Transcription-PCR (RT-PCR):        
To extract RNA, 10 mL yeast cultures were grown under appropriate conditions with the necessary 
treatments as described above. Samples were pelleted by centrifugation at 3000 g for 3 min. at 4°C and 
washed twice with ice-cold AE buffer (50 mM sodium acetate, pH 5.2 and 10 mM EDTA, pH 8.0). 
The pellet was then re-suspended in 400 µL ice-cold AE buffer and 40 µL of 10 % SDS was added, 
followed by the addition of 440 µL of phenol (pH 5.2). Samples were then chilled in a dry ice/ethanol 
bath (made by crushing dry ice to powder and then mixing it with 95% ethanol to form a thick slurry 
mixture) for 5 min. and then transferred to a 65°C water bath for 5 min. followed by vigorous vortex-
mixing for 30 s. After repeating this freeze/thaw/vortex cycle, samples were centrifuged at 16,000 g for 
7 min. and the aqueous layers were transferred to micro-centrifuge tubes for standard phenol-
chloroform extraction and ethanol precipitation of RNA. 
For reverse-transcription, 12μg RNA samples were treated with DNAse I (New England Biolabs) and 
approximately 1μg of this DNA-free-RNA was used for cDNA synthesis using the Super Script II 
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reverse transcriptase reaction (Biorad) according to the manufacturer’s instructions. For quantification, 
qPCRs were performed using SYBR green mix (Froggabio) according to the manufacturer’s 
instructions. Transcripts were normalized to 25S rRNA and the levels were calculated by the 2-ΔΔCT 
method (44). All experiments were performed at least three times and the average values are shown 
with standard deviations shown as error bars. Primer sequences are listed in Appendix G. 
2.10 Chromatin Immunoprecipitation (ChIP): 
Yeast strains were inoculated in 50 mL of SC medium at 30˚C and grown to an optical density A595 
(O.D.) of 0.5-0.6.The cultures were then treated with rapamycin (or DMO as a control) as mentioned 
above for 20 min., followed by cross-linking with 1.1% formaldehyde for 20 min., before quenching 
with 450 mM of glycine for 5 min. The samples were then pelleted by centrifugation and washed with 
ice-cold TBS (20mM Tris-HCl, pH 7.5 and 150mM NaCl), followed by washing with ChIP buffer 
(50mM HEPES-KOH, pH 7.5, 150mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% sodium 
deoxycholate and 0.1% SDS). The samples were then resuspended once again in ChIP buffer and then 
subjected to beating with glass beads followed by sonication to shear chromatin to fragments of ~500 
bp length. Followed by centrifuging the samples for 5 min., NaCl was added to the isolated 
supernatants to a final concentration of 425 mM. A small amount of the supernatant (40μL) was stored 
at -20˚C as input, and the rest of the salt-adjusted supernatant was incubated overnight at 4˚C with 
washed Protein G agarose beads in addition to 1 μg of the appropriate antibody for IP. The following 
day, beads were washed first in ChIP buffer with 275mM NaCl, followed by the ChIP buffer with 
500mM NaCl and then with an additional washing buffer (10mM Tris-HCl, pH 8, 0.25M LiCl, 1mM 
EDTA, 0.5% NP-40 and 0.5% sodium deoxycholate) and finally with Tris-EDTA buffer (10mM Tris-
HCl, pH 8 and 1mM EDTA). Between each buffer wash, the samples were incubated at room 
temperature for 4 min. The beads were then incubated with ChIP elution buffer (50mM Tris-HCl, pH 
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7.5, 10mM EDTA and 1% SDS) for 10 min. at 65o C. The samples were then centrifuged at 8000 g and 
the supernatants were treated with proteinase K (BioShop) at 42o C for 1 hour, and then transferred to 
65o C for 4 hours to overnight to reverse cross-links. Each ChIP experiment was performed at least 
three times and the average of quantitative PCR (qPCR) analyses are presented relative to levels at an 
untranscribed region of chromosome V (Chr V), with standard deviations shown as error bars. The 
value for each sample is calculated as follows: 
Percent Chr V levels = 100*2^(-ΔCt[normalized ChIP to Chr V levels]). Primer sequences used for 
qPCR are listed in Appendix E.
2.11 Genomic DNA Extraction:  
10 mL of yeast culture was incubated in the appropriate media overnight to saturation. The cells were 
centrifuged at 3000 g for 5 min. the next day, followed by the pellet being resuspended in 0.5 mL of 
sterile water and washed. 0.2 mL of extraction buffer (40 μL PEG 3500 50% w/v, 36 μL LiAc 1.0 M, 
25 μL boiled SS-carrier DNA, 10 μL cleaned PCR product & 40 μL ddH2O), 0.3 g of acid-washed 
baked glass beads and 0.2 mL of phenol-chloroform (1:1) were then added to the pellet, followed by 
vortexing it for 3 min. After adding 0.2 mL of TE, pH 7.4 to the samples, the cells were then 
centrifuged at top speed for 5 min., followed by the aqueous layer being transferred to a new microfuge 
tube. 1 mL of absolute ethanol was then added, and mixed by inversion followed by centrifugation at 
top speed for 1 min. The supernatant was subsequently removed by decanting, and the pellet 
resuspended in 0.4 mL of 1X TE (10XTE buffer has 440 mL ddH2O, 50 mL 1 M Tris-HCl pH 7.5 and 
10 mL 500 mM EDTA pH 8.0). 3 μL of 10 mg/mL RNAse A was added to the cells and incubated at 
37°C for 5 min. 10 μL of 4 M ammonium acetate and 1 mL of absolute ethanol were added to re-
precipitate the DNA. Samples were then inverted and centrifuged at top speed for 2 min. Finally, the 
supernatant was removed and the pellet was resuspended in 50 μL of TE. 
19
2.12 Microscopy:
The strains (parental and Ubc9-FRB) were incubated at 30o C in SC media overnight, and the cultures 
were treated with 1 mg/mL rapamycin for 0, 15 or 30 minutes. A drop of the strain(s) was placed on a 
glass slide and observed under a light microscope at 100 X magnification. Images were recorded using 
the microscopy software Motic Images 2.0. 
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Chapter 3: Results
3.1 Preparing the Anchor away strains
To examine the effects of the absence of nuclear sumoylation on cell functions, particularly 
transcription, we applied the anchor away system to the sole conjugating enzyme, Ubc9. A 
homologous recombination-based transformation procedure was used to generate the anchor-away 
strain which expresses Ubc9 fused to the FRB domain of mTOR. 
The pFA6a-FRB-KanMX plasmid (which had an FRB domain fused to the KanMX marker), used as a 
PCR template to generate a cassette consisting of the FRB domain fused to the KanMX marker, was 
flanked by regions of homology with sequences surrounding the stop codon of UBC9. After 
confirming the size of the expected product using gel electrophoresis (Fig 6A), a phenol chloroform 
extraction was done on the PCR products to clean it from other impurities. This was then transformed 
into a strain where the human FKBP12 protein had been fused to the yeast ribosomal protein RPL13A. 
The homologous recombination-based transformation resulted in the generation of the anchor-away 
strain which expressed Ubc9 fused to the FRB domain of mTOR. The parental strain also contains a 
mutated TOR1 making it resistant to rapamycin. The transformation was done on a YPD plate with the 
antibiotic G418 (0.3mM) in it in order to select for the colonies which had incorporated the KanMX 
marker in them, providing resistance against the antibiotic. Successful transformants were selected and 
were further grown in YPD media with G418 in order to fully confirm whether the strains had the 
KanMX insert successfully present in them. Genomic DNA from the strains that grew successfully was 
extracted, their concentrations measured and tested by PCR for their presence of the inserted fusion 
protein (Fig 6, B & C). Successful transformants were then confirmed by sequencing and Ubc9-FRB 
fusion strain 1 was selected to proceed to further experiments. A control western blot assay was also 
performed on the Ubc9-FRB fusion strain lysates to confirm the presence of the FRB domain (Fig 6 
D).
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Figure 6: Preparing the Ubc9-FRB Anchor Away Strain
A: The pFA6a-FRB-KanMX plasmid (which had an FRB domain fused to the KanMX marker) was amplified by PCR 
using primers to tag the forward and reverse base-pairs of Ubc9. The size of the expected product (~ 2000 bps) was 
confirmed by gel electrophoresis. After cleaning the PCR products with a phenol chloroform extraction, this was later 
transformed into a strain where the human FKBP12 protein was fused to the yeast ribosomal protein RPL13A. The 
homologous recombination-based transformation resulted in the generation of the anchor-away strain which expressed 
Ubc9 fused to the FRB domain of mTOR. B: Genomic DNA from the strains that grew successfully was extracted and 
tested by PCR for their presence of the inserted fusion protein. A & D primers for Ubc9 were used to amplify the region of 
interest. Bands around ~3000 bps indicated that the Ubc9 gene locus, 1118 bps long, was successful in incorporating the 
FRB-KanMX plasmid, ~ 2000 bps long. C: Further PCR was performed using an unrelated genomic DNA without the 
fusion segment as a control. The results confirmed that the Ubc9-FRB fusion DNA (~3000 bps) was longer than the control 
DNA (1118bps) by roughly the same size as the plasmid it incorporated (~ 2000 bps). D: A control western blot assay 
performed on the Ubc9-FRB fusion strain lysate probing for FRB revealed its presence in the strain, while being absent in 
control strains as expected.
3.2 Testing the Ubc9 anchor away strain
To confirm that the Ubc9 anchor away fusion strain (“Ubc9-FRB”) was indeed deficient in nuclear 
sumoylation when exposed to rapamycin, cell lysate from the fusion strain (as well as from the parental 
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strain) was extracted after treating the cells with rapamycin for various times, and analyzed by western 
blot with a SUMO antibody. As expected, while the parental strain was unaffected by rapamycin 
treatment, the Ubc9-FRBstrain showed a marked depletion of sumoylated proteins, from as quickly as 
five min. after the treatment (Fig 7). This quick activation of the anchor away system was expected, 
considering that rapidity was one of the advantages of using this system (11). Levels of the constitutive 
GAPDH protein, used as a control in the western blot, remained fairly consistent, even with the 
depletion of sumoylated proteins in this blot (Fig 7). The dramatic disappearance of sumoylation from 
the lysate in the rapamycin-treated Ubc9-FRB strain suggests that most sumoylated proteins are 
nuclear.
This assay also showed that the system was successful in conditionally depleting sumoylation with 
rapamycin treatment. 
 To determine the localization of sumoylated proteins in the cell, a chromatin fractionation was then 
performed, followed by a SUMO western blot. The results show that the great majority of sumoylated 
proteins are associated with chromatin (Fig 8). Upon rapamycin treatment, these levels, once again, 
showed a marked depletion indicating that the anchor away system is effective in blocking nuclear 
sumoylation events (Fig 8).The association of most SUMO targets with chromatin indicates that 
SUMO likely participates in many aspects of chromatin biology. This result was also consistent with 
other studies which detected a high level of sumoylation associated with promoters of active genes.
There is a conspicuous band seen on the SUMO blot in this assay, weighing around 42 kDa (Fig 8). 
We hypothesize that this band corresponds to the Ubc9-FRB fusion protein itself (~ 30 kDa) 
conjugated to SUMO (~ 12 kDa). If so, the presence of this band solely in the chromatin fraction, even 
with rapamycin treatment, would indicate that the enzyme was present in the nucleus, contradictory to 
the theory behind the anchor-away technique. Nonetheless, the conditional depletion of sumoylated 
proteins with the treatment suggests that the enzyme activity was impaired simply by association with 
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rapamycin. It was also notable that this band is more intense when treated with rapamycin, implying 
that this treatment resulted in Ubc9 being unable to conjugate SUMO to its target proteins and 
essentially remaining stuck with the peptide (Fig 8).
Figure 7: Depletion of sumoylated proteins is rapid upon rapamycin addition
Cell lysates were extracted from the parental and the Ubc9-FRB fusion strains and a western blot assay was performed 
using a SUMO antibody. While the parental strain was unaffected with rapamycin treatment, the Ubc9-FRB fusion strain 
showed a rapid decrease in sumoylated proteins in as little as 5 min. indicating that the anchor away system blocked de 
novo sumoylation rapidly. GAPDH is shown as a control.
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Figure 8: Most sumoylated proteins are present on the chromatin
Chromatin fractionation followed by a western blot analysis of the Ubc9-FRB fusion strain revealed that most sumoylated 
proteins are found associated with chromatin. There is a significant decrease in chromatin-associated sumoylation upon 
treatment with rapamycin (30 min.) indicating that the anchor away system is effective. Rpb1 (largest subunit of RNA 
Polymerase II) and GAPDH are shown as controls for the chromatin and soluble fractions, respectively.
In order to confirm the transit (or lack of transit) of the Ubc9 enzyme from the nucleus to the 
cytoplasm upon rapamycin treatment, a chromatin fractionation was once again performed followed by 
a western blot assay probing for Ubc9. The Ubc9 band (~ 30 kDa) did not disappear from the 
chromatin fraction with rapamycin treatment, as would be expected if Ubc9-FRB was re-localized to 
the cytoplasm (9A). There were two additional sets of bands seen in the Ubc9 blot (around 37 kDa and 
42 kDa). The 42 kDa band is most likely the Ubc9-FRB fusion protein conjugated to the SUMO 
peptide (Fig 9A). This hypothesis is strengthened as these bands are also seen on the corresponding 
SUMO blot. The increased intensity of the 42 kDa band in the chromatin fraction, as seen in Fig 8, is 
seen here as well with rapamycin treatment, showing that Ubc9 was unable to conjugate SUMO to its 
target proteins, thus leaving the enzyme associated with the peptide (Fig 9B). However, rapamycin 
treatment did deplete sumoylated proteins as expected in the strain, strengthening our hypothesis that 
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binding of rapamycin to Ubc9-FRB itself impairs its SUMO conjugation activity, but does not cause 
the evacuation of nuclear Ubc9 to the cytoplasm. Regardless of the mechanism, the Ubc9-FRB strain 
that we generated is effective in conditionally and rapidly blocking sumoylation, and further analysis 
was carried out with this strain (Fig 9B).
Figure 9: Ubc9 may not be leaving the nucleus upon rapamycin treatment in the Ubc9-FRB strain
A: Chromatin fractionation followed by a western blot analysis of the Ubc9-FRB fusion strain revealed that the conjugating 
enzyme Ubc9 does not dissociate from chromatin upon rapamycin treatment. * indicates the Ubc9 band (~ 30 kDa) while 
the ** in the Ubc9 and SUMO blots indicate the Ubc9 fused with SUMO (~ 42 kDa). The extra bands seen ~ 37 kDa are 
most likely non specific bands. B: Although the evacuation of the Ubc9 enzyme is theoretically required for the anchor-
away system to work, the depletion of sumoylated proteins upon rapamycin treatment indicates that the system is effective 
regardless of the enzyme’s presence in the nucleus. As indicated in figure 7, most sumoylated proteins are found associated 
with the chromatin fraction. H3 and GAPDH are shown as controls for the chromatin and soluble fractions, respectively.
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3.3 Comparing the sumoylation levels of the anchor away strain with the parental strain
We wished to determine whether the FRB fusion to Ubc9 adversely affects its function by comparing 
protein sumoylation levels in the Ubc9-FRB strain (in the absence of rapamycin) with sumoylation 
levels in the parental strain. Lysate from the Ubc9-FRB fusion strain was extracted and analyzed by 
western blot with a SUMO antibody to compare the sumoylation levels in the parental strain and an 
unrelated control strain. The analysis revealed that the fusion strain has lower levels of SUMO-
conjugation, even in the absence of rapamycin, compared to the parental strain and a control strain (Fig 
10). As we previously observed (Fig 7), upon rapamycin treatment, the sumoylation levels in the fusion 
strain dropped further while the parental and control strains remained unaffected (Fig 10).This 
indicates that a caveat of using the strain is that it displays reduced basal sumoylation levels, even 
when grown in the absence of rapamycin. Nonetheless, we reasoned that the strain is suited for two 
types of analysis: (1) It can be used to study the consequences of constitutively reduced levels of 
sumoylation, by comparing the parental strain and the Ubc9-FRB strain in the absence of rapamycin, 
and (2) it can be used to study the effects of a rapid, inducible loss of sumoylation, by treating the 
Ubc9-FRB strain with rapamycin.
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Figure 10: The Ubc9-FRB fusion strain starts off with a lower level of sumoylation compared to other strains 
Lysate extraction followed by western blot analysis of the Ubc9-FRB fusion strain showed that it had significantly lower 
basal levels of sumoylation to begin with, compared to the parental and control strain, even before rapamycin treatment. 
This level reduced further upon treating with rapamycin (30min.) in these strains, although the control strains remained 
unaffected with the same treatment. GAPDH was used as a control (See Appendix A for the western blot assay using lysate 
volumes normalized to the band intensities).
3.4 Characterizing the growth patterns of the anchor away strain
In order to determine whether reduced sumoylation affects cell growth, we compared growth patterns 
of the Ubc9-FRB fusion strain with the parental strain, using a “spot assay” on standard rich medium 
(YPD) and on YPD medium supplemented with rapamycin (1 μg/mL). The strains had comparable 
growths on the standard YPD plates over 2 - 3 days (Fig 11). The parental strain (used as the control) 
grew similarly in the YPD plates supplemented with rapamycin. However, the Ubc9-FRB fusion 
strains did not grow on the rapamycin plates indicating that rapamycin was uniquely toxic for these 
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strains (Fig 11). Since the Ubc9-FRB strain displays dramatically reduced sumoylation upon exposure 
to rapamycin, it could be surmised that some level of sumoylation is essential for yeast cell survival.
Figure 11: A functional Ubc9 is essential for yeast survival 
A spot assay showing the growth of yeast strains on standard (YPD) plates with/without rapamycin (1 μg/mL).It is to be 
noted that while the control and fusion strains grew similarly on the standard plates, the Ubc9-FRB fusion strains did not 
grow on rapamycin plates indicating that the system is effective and that a functional Ubc9 is essential for yeast survival. 
A liquid growth assay was then conducted to further explore the growth impairment in the Ubc9-FRB 
fusion cells and to narrow down the timeframe that the cells start to die off. The fusion strain as well 
as the parental strain, which was used as the control in this assay, were treated with rapamycin (or 
with DMSO as a control), and the optical densities (ODs) of cultures were measured across 34 hours. 
The untreated parental (parental + DMSO), untreated anchor away strain (anchor-away +DMSO) and 
the treated parental strain (parental + rapamycin) had similar growth patterns throughout the assay, 
showing a normal exponential growth curve that enters a flat, stationary phase (peaking at an average 
OD of 3.93, 3.87 & 3.64 respectively) (Fig 12). The treated Ubc9-FRB strain (anchor-away + 
rapamycin) began to plateau from the 6 – 10 hour mark and showed no further increase in cell density 
for the duration of the assay, ending with an average OD of 0.970. It is of interest that the treated 
anchor away curve showed a similar trend to the other three curves until around the five hour mark, 
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from which it began to diverge (Fig 12). Since most of the experiments described below were 
performed within an hour of rapamycin treatment, the results obtained are most likely due to the drop 
in sumoylation levels, and are not a side-effect of the cells dying in general. 
Light microscopy analysis revealed that there was a greater number of dead yeast cells, characterized 
as sessile, dark and clumped structures, observed in the Ubc9-FRB strain compared to the parental 
strain after rapamycin treatment (Fig 13). The assay was performed at two time intervals (15 & 30 
min.) after the initial rapamycin treatment. 
Figure 12: The Ubc9-FRB fusion strain grew similarly to the parental strain until rapamycin treatment
A liquid growth assay showing the growth of the parental and Ubc9-FRB fusion strains measured after rapamycin 
(or DMSO control) treatment across 35 hours. The fusion strain and the parental strain had similar growth rates. 
However, although the parental strain was unaffected with rapamycin treatment, the fusion strain started to die off 
4-5 hours after treatment. The measurements were obtained using a spectrophotometer after the initial treatments 
(1 μg/mL) and were averaged across three replicates. A polynomial trend line was chosen to illustrate the trend. 
(See Appendices B, C & D for the raw data).
(Result & Fig. 12 obtained from: Farhaan Khan)
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Figure 13: Rapamycin treatment resulted in the accumulation of dead Ubc9-FRB fusion cells 
Microscopy revealed that rapamycin treatment resulted in the increased accumulation of dead cells for the Ubc9-
FRB fusion strain compared with the parental strain. The parental and Ubc9-FRB fusion strains were incubated in 
rapamycin for 0 min (lane 1), 15 min. (lane 2) and 30 min. (lane 3). Dead yeast cells were defined as sessile, dark 
and possibly in clusters. Samples were placed on a slide and viewed through a light microscope at 100 X 
magnification. Images were acquired from a microscopy program which took pictures from the microscope’s field 
of view.  
(Result & Fig. 13 obtained from: Farhaan Khan)
3.5 Effects of reduced sumoylation on transcription of constitutive genes
Once the Ubc9-FRB strain was characterized, sumoylation was blocked by adding rapamycin 
to the cells in order to determine the effects of reduced sumoylation on transcription of 
constitutive genes. We performed RT-PCR and ChIP analyses, followed by quantitative PCR 
assays for both these experiments. The DBP2 gene was chosen as a model gene to examine 
due to its high expression levels, and because DBP2 transcripts have a very short half-life (3 
min.), which means that steady-state RNA levels better reflect transcription rates of the gene.
Although rapamycin was not expected to affect the parental strains, the DBP2 transcript 
levels decreased following 30 min. of rapamycin treatment, suggesting that rapamycin itself 
has a negative effect on DBP2 expression (Fig 14). However, levels of DBP2 were 
dramatically lower in the Ubc9-FRB strain compared to the parental strain, even in the 
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absence of rapamycin (Fig 14). Addition of rapamycin did not change DBP2 levels in the 
Ubc9-FRB strain, implying that further blocking sumoylation did not have a noticeable effect 
on its expression. To verify that our procedure was effective in detecting changing levels of 
DBP2 transcription, we examined DBP2 mRNA levels in an Rpb1-FRB strain. In the control 
strain, rapamycin treatment triggers the anchor-away system to sequester Rpb1, the largest 
subunit of RNA Polymerase II, from the nucleus, effectively blocking transcription by RNA 
Polymerase II transcribed genes in these strains. Indeed, treatment of the Rpb1-FRB strain 
resulted in an expected decrease in the mRNA levels of the DBP2gene (Fig 14). Our analysis 
of the DBP2 suggests that constitutively reduced levels of sumoylation result in impaired 
expression of the gene, but that further reduction of sumoylation, by treatment of Ubc9-FRB 
with rapamycin, has no effect.
Figure 14: The effects of blocking sumoylation on the mRNA levels of DBP2, a constitutive gene, in the Ubc9-FRB 
fusion strain 
The mRNA levels of the DBP2 gene in the Ubc9 fusion strain were compared with the parental control strain 
after alpha-factor and rapamycin treatment. The results showed that rapamycin had an effect on the parental 
strain for the gene. The mRNA levels of the Ubc9-FRB fusion strain, however, did not change, even with 
rapamycin treatment. Notably, the Ubc9-FRB fusion strain had lower levels of the DBP2 transcript compared to 
the parental strain, to begin with. The control Rpb1-FRB fusion strain, where the addition of rapamycin triggers 
Rpb1 evacuation from the nucleus subsequently resulting in decreased transcription, expectedly showed a drop 
in DBP2 mRNA levels. Assays were normalized to 25S rRNA and the results were averaged across 4 replicates, 
with * p <0.05. 
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To support our RT-PCR analyses, we next examined the DBP2 gene by Rpb1 and SUMO 
ChIP. The Rpb1-FRB strain was again used as a control. ChIP analysis shows that there is 
less SUMO and Rpb1 associated with the promoter of DBP2 in the untreated Ubc9-FRB 
strain than in the control strain (Fig 15). Interestingly, no further reduction in SUMO levels 
was observed in the Ubc9-FRB strain on the DBP2 promoter with rapamycin treatment (Fig 
15). This suggests that the minimal level of promoter-associated sumoylation was already 
achieved on DBP2, even before rapamycin treatment. As expected, the Rpb1-FRB strain 
showed a significant reduction in the Rpb1 levels with rapamycin treatment. For the Ubc9-
FRB strain, there was also no change in the Rpb1 occupancy levels on the DBP2 promoter 
with rapamycin treatment (Fig 15). Although rapamycin did not further reduce promoter-
associated SUMO levels on DBP2, this ChIP analysis correlates promoter-associated 
sumoylation levels with transcription levels, suggesting that SUMO has a positive effect on 
DBP2 expression. To determine whether this is a general phenomenon, three other transcripts 
were analyzed, including a highly-expressed, but more stable mRNA, PMA1, a ribosomal 
protein, RPP2B, and an RNA transcribed by RNA polymerase III, sNR52. As shown in 
Appendix E & F, variable effects were observed.
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Figure 15: Blocking sumoylation does not alter recruitment of Rpb1 to the DBP2 constitutive gene promoter in 
the Ubc9-FRB fusion strain.
Several ChIP assays were performed to look at Rpb1 recruitment to the DBP2 constitutive gene promoter. The 
results showed that there wasn’t a marked difference in the polymerase recruitment for DBP2 in the Ubc9 fusion 
strain with rapamycin treatment. SUMO ChIP results, looking at the SUMO levels on these promoters, also 
showed that even with rapamycin addition, there wasn’t a further reduction in SUMO levels for the DBP2 gene 
promoter, perhaps because they start off with lower SUMO levels even before rapamycin treatment. The control 
Rpb1-FRB fusion strain, where the addition of rapamycin triggers Rpb1 evacuation from the nucleus, 
expectedly showed a drop in Rpb1 levels at the DBP2 promoter, upon rapamycin treatment. Assays were 
performed after alpha-factor treatment, normalized to Chr V (an untranscribed region of the chromosome) and 
the results were averaged across 3 replicates, with * p <0.05. 
3.6 Effects of reduced sumoylation on histone marks
Trimethylation of histone H3 at Lys 4 (H3K4me3) and acetylation of histone H3 at Lys 9 
(H3K9ac) are histone modifications that are considered indicators of genes that are 
transcriptionally active (17). To determine whether reduced sumoylation results in changes to 
transcription-associated histone marks, we performed Western Blot assays of the lysates 
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extracted from the Ubc9-FRB fusion strain (and the control parental strain) with or without the 
treatment of rapamycin. The strains were probed for the active histone marks H3K4me3 & 
H3K9ac. Although there was significantly less global sumoylation in the Ubc9-FRB strain, 
which was further depleted after rapamycin treatment, cellular levels of H3K4me3 or H3 K9ac 
marks in these strains were not affected (Fig 16).
Figure 16: Rapamycin treatment resulted in no difference in various histone marks in the Ubc9-FRB strains
Western Blots probing the parental and Ubc9-FRB fusion strains for histone marks H3K4me3 & H3K9ac after a rapamycin 
treatment condition revealed no difference. As expected, the Ubc9-FRB fusion strain showed a marked depletion in 
sumoylation upon rapamycin treatment indicating that sumoylation levels do not influence the H3K4me3 or H3K9ac marks 
globally in the fusion strain. 
(Fig. 16 obtained from: Akhi Akhter)
ChIP assays were then conducted to determine whether levels of the H3K9ac histone mark on 
various constitutive gene promoters was affected by impaired sumoylation in the Ubc9-FRB 
fusion strain. The Rpb1-AA strain, which was used as a control, showed a significant reduction 
in the H3K9ac mark with rapamycin treatment, indicating that reduced transcription of DBP2 
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and RPP2B triggered by the anchor-away system was associated with lower levels of these 
activating marks on their promoters (Fig 17). In the Ubc9-FRB strain, the H3K9ac 
modification levels on the selected gene promoters were unaffected by rapamycin treatment 
(Fig 17). However, an examination of levels of the histone modification in untreated Ubc9-
FRB cells shows that both the DBP2 and RPP2B gene promoters have significantly lower 
levels of H3K9ac compared with the control (Fig 17). This correlates reduced sumoylation 
levels on promoters of these genes (Figs 15 and Appendix F) with reduced levels of a histone 
mark that is associated with active transcription.
Figure 17: Rapamycin treatment resulted in no difference in the H3K9ac mark in the selected Ubc9-FRB strain 
promoters 
The levels of histone mark H3K9ac on various constitutive promoters of the Ubc9-FRB fusion strain were 
examined. Although the control Rpb1-AA strain showed a reduction in the mark with rapamycin treatment, the 
Ubc9 strain did not show the same trend. H3K9ac is mostly associated with active transcription and this 
coincided with the reduced transcription seen in the Rpb1-AA strain upon rapamycin treatment. Experiments 
were performed and the results were averaged across 3 replicates and normalized to ChrV (an untranscribed 
region of the chromosome) levels, followed by normalizing it to total H3 levels. Assays were conducted after 3 
hours of alpha factor treatment with * p <0.05. 
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3.7 Enzymes responsible for the rapid turnover of SUMO
Although rapamycin-induced inhibition of Ubc9 activity is expected to conditionally and rapidly block 
only de novo sumoylation, the total sumoylated proteins in the Ubc9-FRB strain diminish rapidly, in as 
little as in 5 min. (Fig 7). This indicates that most SUMO modifications are highly transient involving 
rapidly sumoylating new proteins in conjunction with a quick turnover of already sumoylated proteins. 
This observation poses an interesting question: What enzyme(s) is responsible for maintaining this 
quick SUMO turnover? There were three candidate possibilities which we considered to be responsible 
for the rapid disappearance of sumoylated proteins: degradation of sumoylated proteins through the 
26S proteasome, or removal of SUMO modifications by either the Ulp1 or Ulp2 SUMO-specific 
proteases (i.e. desumoylation enzymes). While the 26S proteasome degrades polyubiquitinated proteins 
(and thus, indirectly, sumoylated proteins as discussed in section 1.5 in the Introduction), the SUMO 
proteases cleave the bond between SUMO and its substrate (discussed in section 1.4 in the 
Introduction). Several experiments were performed to narrow down the enzyme(s) involved. 
To determine whether the 26S proteasome was implicated, Ubc9-FRB cells were treated with the 
proteasome inhibitor MG132 prior to treatment with rapamycin. With controls, four conditions were 
tested: strains without MG132 or rapamycin, strains without MG132 but treated with rapamycin for 30 
min., strains with MG132 but no rapamycin and strains with MG132 and treated with rapamycin for 30 
min. (Fig 18). A western blot assay probing for SUMO showed that despite the lack of a functioning 
26S proteasome, there was still a depletion of sumoylated proteins with rapamycin treatment (Fig 18). 
This indicated that the degradation of sumoylated proteins by the proteasome was probably not the 
reason for the quick SUMO turnover. To ensure that the MG132 treatment was effective at blocking 
the 26S proteasome, lysates from the samples were analyzed with the FK1 antibody, which recognizes 
polyubiquitinated proteins of high molecular weight. Indeed, MG132 treatment stabilized ubiquitinated 
proteins, indicating that the proteasome had been inactivated (Fig 18).
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To test if Ulp2 was responsible for the rapid turnover of SUMO signal, ULP2 was deleted from the 
Ubc9-FRB anchor-away strain using a URA3-MX3 deletion cassette and homologous recombination. 
A western blot assay of the lysates extracted (with or without rapamycin treatment) from the ULP2 
deleted Ubc9-FRB fusion strain probing for SUMO showed the same pattern as the experiments done 
using the Ubc9-FRB fusion strain with ULP2 intact (Fig 19). It is to be noted that the ulp2Δ strain had 
more proteins that had higher molecular weights than the parental anchor-away strain, a characteristic 
expected of a strain lacking the SUMO protease Ulp2 (Fig 19). However, depletion of sumoylated 
proteins with rapamycin treatment in the ulp2Δ was comparable to the parental Ubc9-FRB fusion strain 
(Fig 19). This indicates that desumoylation by Ulp2 is also not responsible for the rapid loss of 
sumoylation during rapamycin-induced inactivation of Ubc9. Future analysis will determine whether 
the essential SUMO protease Ulp1 is responsible for the phenomenon.
Figure 18: 26S proteasome is most likely not responsible for the depletion of sumoylated proteins upon rapamycin 
treatment in the Ubc9-FRB fusion strain
A Western Blot assay of the Ubc9-FRB fusion strain lysates after MG132 and rapamycin treatment was performed probing 
for SUMO and FK1. (A & B) From left to right Lanes 1-2: contain lysates incubated for 30 min. in DMSO, Lanes 3-4: 
lysates incubated in 75µM MG132. Lanes 2 & 4 were treated with rapamycin. Lane 4 of A showed that there was depletion 
of sumoylated proteins with rapamycin treatment, even when the 26S proteasome was not functioning due to MG132 
treatment. Lanes 3 &4 from B showed the presence of poly-ubiquitinated proteins, recognized by the FK1 antibody, when 
treated with MG132, implying that it was successful in blocking the 26S proteasome. H3 is used in A as a control. 
(Result & Fig. 18 obtained from: Farhaan Khan)
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Figure 19: Ulp2 is most likely not responsible for the depletion of sumoylated proteins upon rapamycin treatment in the 
Ubc9-FRB fusion strain
A Western Blot assay of the Ubc9-FRB fusion strain and Ulp2Δ strain, after rapamycin treatment, was performed probing 
for SUMO. From left to right, Lanes 1-2: contain the anchor away strain lysates incubated without (lane 1) or with (lane 2) 
rapamycin, Lanes 3-4: Ulp2Δ strain lysates incubated without (lane 3) or with (lane 4) rapamycin. The depletion of 
sumoylated proteins with rapamycin treatment persisted even for the Ubc9-FRB anchor-away strains with deleted ULP2.
(Result & Fig. 19 obtained from: Farhaan Khan)
. 
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Chapter 4: Discussion
Sumoylation, the covalent reversible attachment of the SUMO peptide to lysine residues of cellular 
proteins, affects proteins in a vast range of cellular processes. Due to the finding that proteins involved 
in transcription comprise one of the largest groups of sumoylation targets, and that sumoylated proteins 
are associated with transcriptionally active genes, particularly at their promoters, it is likely that 
sumoylation functions in regulating transcription and other levels of gene expression. The sole SUMO 
conjugating enzyme Ubc9’s recruitment to a number of different inducible gene promoters when they 
were activated also implies a general role for this PTM during the gene induction process (9). Since the 
exact function of protein sumoylation on gene promoters still remains largely unknown, a system to 
study global sumoylation by blocking the process can be extremely powerful. The anchor-away system 
that was developed and characterized in this project was used for this purpose and helped examine the 
effects of impaired sumoylation under essentially normal growth conditions. The distinct advantage of 
using this system was that it allowed for the conditional and rapid inactivation of Ubc9, tantamount to 
preventing de novo sumoylation. Both SMT3, the only SUMO isoform in yeast, and UBC9, the only 
known SUMO conjugating enzyme, are essential genes making the usage of null mutants impossible 
(22). Although there have been previous studies using a temperature sensitive ubc9-1 strain for 
examining the effects of reduced cellular sumoylation (9), the experiments using the strain had to be 
performed during heat shock due to the strain expressing an unstable mutant form of the enzyme, only 
inactive at elevated temperatures. Further, the overall sumoylation was abnormal with the strain 
displaying growth defects, even at normal temperatures. Using the novel Ubc9-FRB strain no longer 
relied on the previously utilized stress inducing techniques which could increase the likelihood of 
introducing experimental artifacts and was thus, theoretically superior (11). Characterizing this strain 
and testing out some of the effects of blocking sumoylation in regulating transcription were the major 
objectives of this project. 
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Sumoylation levels in the Ubc9-FRB fusion strain compared to the parental strain and an additional 
control strain showed that there were much lower levels of sumoylated proteins in this strain, which 
could be even further reduced with rapamycin. A growth assay on solid medium (“drop test”), liquid 
growth assay and microscopy experiments revealed that while the parental strain and the Ubc9-FRB 
strain grew similarly on standard YPD plates, with similar cell densities and were visually similar 
under the microscope, rapamycin treatment resulted in the latter strain not being able to survive and 
were visually seen as sessile and in clusters. The ODs of these strains diverged from around 4-5 hours 
after rapamycin treatment from the parental strains, which were unaffected. This showed that 
sumoylation was essential for cell viability and conditionally blocking de novo nuclear sumoylation 
events by rapamycin treatment was lethal for the cells. However, it is also to be noted that, in the 
absence of rapamycin, the Ubc9-FRB strain grew fairly similarly to the parental strain despite having 
constitutively lower levels of sumoylation, indicating that this characteristic of the strain was not lethal. 
Consistent with the western blot analysis, ChIP analysis of some gene promoters showed lower 
sumoylation levels compared to the control strain. Combined with the mRNA analysis, for the 
constitutive gene DBP2, there were much lower levels of the transcript in the Ubc9-FRB fusion strain 
coinciding with the lower SUMO levels on this promoter. These results suggest that sumoylation is 
mostly associated with increased transcription and RNA Pol II recruitment in constitutive genes. This 
effect, however, was not seen on all the genes examined indicating that sumoylation may have different 
effects on different constitutive genes, perhaps depending on which transcription factors are involved. 
It is also to be noted that the lower half-life of the DBP2 transcript means that steady-state RNA levels 
better reflect transcription rates of the gene compared to the others examined. .A further drop in global 
sumoylation, induced by rapamycin in the Ubc9-FRB fusion strain, did not further reduce promoter-
associated sumoylation, and also did not further drop transcription levels suggesting that the minimal 
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level of promoter-associated sumoylation was already achieved on DBP2, even before rapamycin 
treatment. 
Blocking sumoylation in the Ubc9-FRB fusion strain did not alter the levels of various activating 
histone marks globally. The levels of the activating mark H3K9ac on different constitutive gene 
promoters also showed a similar trend in the fusion strain as blocked sumoylation did not alter these 
levels. However, it was once again seen that for DBP2 (and for RPP2B), the Ubc9-FRB fusion strain 
started off with much lower levels of the activating mark H3K9ac. Combined with the mRNA analysis 
and previous ChIP assays, the lower sumoylation levels on the DBP2 promoter in the Ubc9-FRB 
fusion strain was associated with lower expression levels of the transcript and with lower levels of the 
activating H3K9ac mark. This indicated that reduced sumoylation is most likely associated with 
decreased transcription levels, at least for the DBP2 gene in these strains. The significant reduction of 
the H3K9ac mark in the Rpb1-FRB fusion strain upon rapamycin treatment indicates that active 
histone marks may be affected by reduced transcription. Thus, it is likely that although lesser 
sumoylation in the Ubc9-FRB fusion strain correlated with lesser H3K9ac marks on the DBP2 
promoter, this could be a consequence of lesser transcription of the gene in these strains to begin with.  
By inhibiting Ubc9 function, the anchor-away system used in this study, triggered by rapamycin, 
theoretically blocks only de novo sumoylation, and all previously sumoylated proteins should have 
been detected if the modification were stable. However, the rapid decrease in sumoylated proteins in 
the Ubc9-FRB fusion strain upon rapamycin treatment indicates that the PTM is surprisingly very 
labile. MG132 treatment, which inhibits the 26S proteasome, did not reverse the rapamycin-triggered 
disappearance of SUMO conjugates, indicating that SUMO conjugates are not necessarily prone to 
rapid degradation. A western blot of the ULP2Δ strain generated from the Ubc9-FRB fusion strain 
revealed that de-conjugation of SUMO by the SUMO protease Ulp2 was also not responsible for the 
depletion of sumoylated proteins. This was slightly expected, as ULP2 is not an essential protease in 
42
yeast (47). ULP1, on the other hand, encodes an essential SUMO protease, with ulp1 null mutants 
being generally lethal (48 & 49). Thus, a temperature sensitive ulp1 strain will be used to confirm 
whether de-conjugation by the enzyme could be the cause for the SUMO depletion observed in 
previous experiments. Considering that the impairment of the Ulp1 protease causes an overall elevation 
in sumoylation levels in yeast cells (50), it is likely that inhibiting the Ulp1 enzyme would rescue the 
drops in SUMO levels seen in the Ubc9-FRB fusion strain with rapamycin treatment, and that the 
enzyme is the primary contributor to the SUMO turnover making it a transient PTM.
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Chapter 5: Future Directions
Future experiments can utilize immunofluorescence microscopy to demonstrate the exact location of 
Ubc9 and confirm its presence in the nucleus after rapamycin treatment. Although not described in this 
thesis, there was a second anchor-away strain designed with an extra green fluorescent protein (GFP) 
tagged next to FRB in the fusion protein. This strain permits the use of GFP microscopy to observe 
Ubc9 in the strain. New strains can be designed for the anchor-away technique to serve as ‘replicates’ 
for the same experiments conducted using the present strain to confirm the consistency of the obtained 
results. Instead of looking at individual transcript levels or gene promoters, a global analysis of 
different mRNA levels and promoters using ChIP seq and RNA-seq can be performed to shed more 
light on the patterns seen on different genes during blocked sumoylation. Although only active histone 
marks H3K4me3 and H3K9ac were looked at in this project, future experiments can look at other 
epigenetically relevant marks and modifications to see if sumoylation is associated with them. Lastly, 
the ULP1 mutant genotype described in this thesis can be made from transforming the Ubc9-FRB 
fusion strain to see if the lack of functioning Ulp1 in these strains could rescue the depletion of 
sumoylated proteins seen with rapamycin treatment. This could confirm Ulp1’s role in the rapid 
SUMO turnover, thus making it essential in maintaining steady-state SUMO levels. Although there are 
caveats in using the strain designed in this project, it still is an extremely useful tool to study global 
sumoylation due to its conditional and rapid ability to block de novo sumoylation in the cells. 
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Appendix
A B  C
APPENDIX A: Comparing the sumoylation levels of the Ubc9-FRB fusion strain with the control strains
A: The initial western blot analysis of the Ubc9-FRB fusion strain with the parental and control strain showed that the 
samples were slightly uneven (Fig 10). B: A coomassie strain of the gel revealed the same with lane 6 having the least 
amount of the lysate. C: The samples were reloaded, after adjusting the volumes for the band intensities measured using 
the ImageJ software. The pattern seen was the exact same as before although since the samples were re-run after a few 
weeks, the amount of sumoylated proteins had decreased.
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APPENDIX B: Liquid growth assay trial data
ODs collected during liquid growth assay. YER013 refers to the parental strain, YJBa001 is the anchor away strain.
TRIAL1
OD
Time Hour YER013+ YER013+ YJBa001+ YJB00a001 
DMSO Rapamycin DMSO +
Rapamycin
TRIAL2
7:00AM        0          0.050                 0.050                0.050              0.050 
9:00AM        2          0.085                 0.087                0.074              0.072 
11:00AM       4          0.182                 0.190                0.140              0.132 
1:00PM         6          0.380                 0.386                0.268              0.212 
5:00PM         10         1.550                 1.510               1.098               0.442 
7:00PM         12         1.922                 1.896               1.660               0.556 
11:00PM        16         2.470                 2.440               2.240               0.648 
7:00AM         24         3.810                 3.750               3.580               0.861 
9:00AM         26         4.170                 4.160               3.980               0.884 
11:00AM        28         4.100                 4.110               4.340               0.903 
1:00PM          30         4.110                 3.960               3.910              0.915 
3:00PM          32         4.060                 3.950               3.970              0.926 
5:00PM          34         4.120                 4.000               4.020               0.942
Time Hour YER013+ YER013+ YJBa001+ YJB00a001 
DMSO Rapamycin DMSO +
Rapamycin
TRIAL3
7:00AM          0           0.050               0.050             0.050               0.050 
9:00AM          2           0.069               0.071             0.069               0.071 
11:00AM         4           0.166              0.170              0.170               0.142 
1:00PM           6           0.381              0.385              0.350               0.251 
5:00PM           10         1.074               1.126              1.014               0.489 
7:00PM           12         1.718               1.672              1.596               0.602 
11:00PM          16         2.176               2.108              2.058               0.772 
7:00AM           24          3.570               3.205              3.235                0.940 
9:00AM           26          3.560               3.370              3.320               0.964 
11:00AM          28         3.640                3.380             3.360                0.980 
1:00PM            30         3.645               3.400              3.420                0.987 
3:00PM            32         3.560               3.365              3.510               1.010 
5:00PM            34         3.570               3.400              3.520               1.023
Time Hour YER013+ YER013+ YJBa001+ YJB00a001 
DMSO Rapamycin DMSO +
Rapamycin
7:00AM          0             0.050               0.050              0.050                 0.050 
9:00AM          2             0.085               0.084              0.085                 0.085 
11:00AM         4             0.168               0.165              0.160                 0.150 
1:00PM           6             0.380               0.365              0.336                 0.254 
5:00PM          10             1.190              1.204               1.060                 0.476 
7:00PM          12             1.978               1.934              1.806                 0.590 
11:00PM         16             2.510               2.450              2.387                 0.660 
7:00AM          24             3.920              3.840               3.631                 0.870 
9:00AM          26             4.202              4.020               3.995                 0.894 
11:00AM         28             4.140              4.120               4.210                0.910 
1:00PM           30             4.120              4.220               4.020                0.934 
3:00PM           32            4.080               4.345               3.940                0.959 
5:00PM           34            4.100               4.200               3.980                0.946
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APPENDIX C: Averaged liquid growth assay data
ODs collected during liquid growth assay. YER013 refers to the parental strain, YJBa001 is the anchor away 
strain.
AVERAGE
TIME Hour       YER013+                  YER013+                YJBa001+                     YJBa001+
              DMSO                   Rapamycin                 DMSO                        Rapamycin
7:00AM 0               0.050   0.050        0.050                             0.050
9:00AM 2               0.080   0.081        0.076                             0.076
11:00AM 4               0.172   0.175         0.157                            0.141
1:00PM 6               0.380   0.379         0.318                            0.23
5:00PM 10             1.271   1.280         1.057                            0.469
7:00PM 12             1.873   1.834         1.687                             0.583
11:00PM 16             2.385   2.333         2.228                             0.693
7:00AM 24             3.767   3.598         3.482                             0.890
9:00AM 26             3.977   3.850         3.765                             0.914
11:00AM 28             3.960   3.870         3.970                             0.931
1:00PM 30             3.958   3.860         3.783                             0.945
3:00PM 32             3.900   3.887         3.807                             0.965
5:00PM 34             3.930   3.867         3.840                             0.970
APPENDIX D: Standard deviation of liquid growth assay trial data
YER013 refers to the parental strain. YJBa001 is the anchor away strain. STDEV was calculated using the excel 
function “=STDEV’
STDEV
TIME Hour                      YER013+          YER013+         YJBa001+           YJBa001+
                            DMSO           Rapamycin            DMSO     Rapamycin
7:00AM 0 0.000 0.000 0.000 0.000
9:00AM 2 0.009 0.009 0.008 0.008
11:00AM 4 0.009 0.013 0.015 0.009
1:00PM 6 0.001 0.012 0.044 0.023
5:00PM 10 0.248 0.203 0.042 0.024
7:00PM 12 0.137 0.142 0.108 0.024
11:00PM 16 0.182 0.195 0.165 0.068
7:00AM 24 0.179 0.344 0.215 0.043
9:00AM 26 0.362 0.422 0.385 0.044
11:00AM 28 0.278 0.424 0.532 0.043
1:00PM 30 0.271 0.419 0.319 0.037
3:00PM 32 0.295 0.493 0.257 0.042
5:00PM 34 0.312 0.416 0.278 0.046
             (Result & Appendices B, C & D obtained from: Farhaan Khan)
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APPENDIX E: The effects of blocking sumoylation on the mRNA levels of various constitutive genes in the 
Ubc9-FRB fusion strain. 
The mRNA levels of various constitutive genes in the Ubc9 fusion strain were compared with the 
parental control strain after rapamycin treatment. The results showed that rapamycin had an effect on the 
parental strain for the PMA1 gene. The mRNA levels of the Ubc9-FRB fusion strain, however, did not 
change, even with rapamycin treatment. Notably, the Ubc9-FRB fusion strain had lower levels of some 
transcripts (such as PMA1) compared to the parental strain, to begin with. The control Rpb1-AA strain, 
where the addition of rapamycin triggers Rpb1 evacuation from the nucleus subsequently resulting in 
decreased transcription, expectedly showed a drop in mRNA levels in all the genes looked at. SNR52, a 
gene transcribed by RNA Pol III, is also used as an additional control. Assays were conducted after 3 
hours of alpha factor treatment, normalized to 25S rRNA and the results were averaged across 4 
replicates, with * p <0.05. 
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ChIP Analysis
APPENDIX F: Blocking sumoylation does not alter recruitment of Rpb1 in many constitutive promoters 
in the Ubc9-FRB fusion strain
Several ChIP assays were performed to look at Rpb1 recruitment to the promoters of various constitutive 
genes. The results showed that there wasn’t a marked difference in the polymerase recruitment for the 
fusion strains. SUMO ChIP results, looking at the SUMO levels on these promoters, also showed that 
even with rapamycin addition, there wasn’t a further reduction in SUMO levels for most promoters, 
perhaps because they start off with lower SUMO levels to begin with. Notably, SNR52, which starts off 
with a much higher level of sumoylation compared to other genes, did indeed show a drop in SUMO 
levels with rapamycin treatment. Assays were conducted after 3 hours of alpha factor treatment, 
normalized to Chr V (an untranscribed region of the chromosome) and the results were averaged across 3 
replicates, with * p <0.05. 
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APPENDIX G: Primers used for qPCR (ChIP and RT-PCR)
Gene Region Primer Sequence (5’ to 3’) Direction
GATAAAAATACACCTTCGTA Forward Promoter
GAATGAGATACAGAAAAGTA Reverse
AAGAGAAGATGGATGGCCCG Forward
DBP2
ORF
TGACATCGATACCTCTGGCG Reverse
GATATTTGGACTTACTCTAA ForwardPromoter 
GTTTAAGCGGTAATAAATTC Reverse
GTCGGTGCTGAAGTCGATGA Forward
RPP2B
ORF
TCCAAAGAGCCCTTACCTTCC Reverse
CAATTATGACCGGTGACGAAAC  ForwardPromoter
AATCGAAACTAATGGAGGGGAG Reverse
CTGGTCCATTCTGGTCTTCTATC Forward
PMA1
ORF
TCAGACCACCAACCGAATAAG Reverse
TGACATTAGCGTGAACAATCTCTG ForwardSNR52 Promoter 
& ORF TTTCAGAAGGAAGGCAACATAAG Reverse
TAAGCGGCATGGACGATGTT ForwardGFD2 ORF
ATGGGCACCACTTTAGGCTC Reverse
